Literature DB >> 35070734

Liver regeneration biology: Implications for liver tumour therapies.

Christopher Hadjittofi1, Michael Feretis1, Jack Martin1, Simon Harper1, Emmanuel Huguet2.   

Abstract

The liver has remarkable regenerative potential, with the capacity to regenerate after 75% hepatectomy in humans and up to 90% hepatectomy in some rodent models, enabling it to meet the challenge of diverse injury types, including physical trauma, infection, inflammatory processes, direct toxicity, and immunological insults. Current understanding of liver regeneration is based largely on animal research, historically in large animals, and more recently in rodents and zebrafish, which provide powerful genetic manipulation experimental tools. Whilst immensely valuable, these models have limitations in extrapolation to the human situation. In vitro models have evolved from 2-dimensional culture to complex 3 dimensional organoids, but also have shortcomings in replicating the complex hepatic micro-anatomical and physiological milieu. The process of liver regeneration is only partially understood and characterized by layers of complexity. Liver regeneration is triggered and controlled by a multitude of mitogens acting in autocrine, paracrine, and endocrine ways, with much redundancy and cross-talk between biochemical pathways. The regenerative response is variable, involving both hypertrophy and true proliferative hyperplasia, which is itself variable, including both cellular phenotypic fidelity and cellular trans-differentiation, according to the type of injury. Complex interactions occur between parenchymal and non-parenchymal cells, and regeneration is affected by the status of the liver parenchyma, with differences between healthy and diseased liver. Finally, the process of termination of liver regeneration is even less well understood than its triggers. The complexity of liver regeneration biology combined with limited understanding has restricted specific clinical interventions to enhance liver regeneration. Moreover, manipulating the fundamental biochemical pathways involved would require cautious assessment, for fear of unintended consequences. Nevertheless, current knowledge provides guiding principles for strategies to optimise liver regeneration potential. ©The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved.

Entities:  

Keywords:  Liver; Liver regeneration potential; Regeneration biology; Therapies; Tumour

Year:  2021        PMID: 35070734      PMCID: PMC8716989          DOI: 10.5306/wjco.v12.i12.1101

Source DB:  PubMed          Journal:  World J Clin Oncol        ISSN: 2218-4333


  460 in total

1.  Bioengineered transplantable porcine livers with re-endothelialized vasculature.

Authors:  In Kap Ko; Li Peng; Andrea Peloso; Charesa J Smith; Abritee Dhal; Daniel B Deegan; Cindy Zimmerman; Cara Clouse; Weixin Zhao; Thomas D Shupe; Shay Soker; James J Yoo; Anthony Atala
Journal:  Biomaterials       Date:  2014-11-26       Impact factor: 12.479

2.  Collagens in the liver extracellular matrix bind hepatocyte growth factor.

Authors:  D Schuppan; M Schmid; R Somasundaram; R Ackermann; M Ruehl; T Nakamura; E O Riecken
Journal:  Gastroenterology       Date:  1998-01       Impact factor: 22.682

Review 3.  Whole liver engineering: A promising approach to develop functional liver surrogates.

Authors:  Fanwei Meng; Abdallah Assiri; Dipok Dhar; Dieter Broering
Journal:  Liver Int       Date:  2017-05-14       Impact factor: 5.828

Review 4.  Liver sinusoidal endothelial cells: Physiology and role in liver diseases.

Authors:  Johanne Poisson; Sara Lemoinne; Chantal Boulanger; François Durand; Richard Moreau; Dominique Valla; Pierre-Emmanuel Rautou
Journal:  J Hepatol       Date:  2016-07-14       Impact factor: 25.083

Review 5.  Angiogenesis in liver disease.

Authors:  Mercedes Fernández; David Semela; Jordi Bruix; Isabelle Colle; Massimo Pinzani; Jaume Bosch
Journal:  J Hepatol       Date:  2008-12-31       Impact factor: 25.083

6.  A hepatocyte growth factor receptor (Met)-insulin receptor hybrid governs hepatic glucose metabolism.

Authors:  Arlee Fafalios; Jihong Ma; Xinping Tan; John Stoops; Jianhua Luo; Marie C Defrances; Reza Zarnegar
Journal:  Nat Med       Date:  2011-11-13       Impact factor: 53.440

7.  Efficient recellularisation of decellularised whole-liver grafts using biliary tree and foetal hepatocytes.

Authors:  Satoshi Ogiso; Kentaro Yasuchika; Ken Fukumitsu; Takamichi Ishii; Hidenobu Kojima; Yuya Miyauchi; Ryoya Yamaoka; Junji Komori; Hokahiro Katayama; Takayuki Kawai; Elena Yukie Yoshitoshi; Sadahiko Kita; Katsutaro Yasuda; Shinji Uemoto
Journal:  Sci Rep       Date:  2016-10-21       Impact factor: 4.379

8.  Stellate Cells, Hepatocytes, and Endothelial Cells Imprint the Kupffer Cell Identity on Monocytes Colonizing the Liver Macrophage Niche.

Authors:  Johnny Bonnardel; Wouter T'Jonck; Djoere Gaublomme; Robin Browaeys; Charlotte L Scott; Liesbet Martens; Bavo Vanneste; Sofie De Prijck; Sergei A Nedospasov; Anna Kremer; Evelien Van Hamme; Peter Borghgraef; Wendy Toussaint; Pieter De Bleser; Inge Mannaerts; Alain Beschin; Leo A van Grunsven; Bart N Lambrecht; Tom Taghon; Saskia Lippens; Dirk Elewaut; Yvan Saeys; Martin Guilliams
Journal:  Immunity       Date:  2019-09-24       Impact factor: 31.745

9.  Population expansion, clonal growth, and specific differentiation patterns in primary cultures of hepatocytes induced by HGF/SF, EGF and TGF alpha in a chemically defined (HGM) medium.

Authors:  G D Block; J Locker; W C Bowen; B E Petersen; S Katyal; S C Strom; T Riley; T A Howard; G K Michalopoulos
Journal:  J Cell Biol       Date:  1996-03       Impact factor: 10.539

Review 10.  iPSC-Derived Liver Organoids: A Journey from Drug Screening, to Disease Modeling, Arriving to Regenerative Medicine.

Authors:  Cristina Olgasi; Alessia Cucci; Antonia Follenzi
Journal:  Int J Mol Sci       Date:  2020-08-27       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.